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Diagnostic value of standardized assays for anti-neutrophil cytoplas-
mic antibodies in idiopathic systemic vasculitis. Anti-neutrophil cytoplas-
mic antibodies (ANCA) are widely used as diagnostic markers for
Wegener’s granulomatosis (WG), microscopic polyangiitis (MPA), Churg-
Strauss syndrome (CSS) and idiopathic rapidly progressive glomerulone-
phritis (iRPGN). The objective of this study was to evaluate the diagnostic
value of ANCA measurement by the indirect immunofluorescence (IIF)
test, and by anti-PR3 and anti-MPO ELISA performed in different
locations, in patients with idiopathic small vessel vasculitis. Fourteen
centers participated in a standardization study of ANCA assays, and
entered a total number of 169 newly diagnosed and 189 historical patients
with idiopathic systemic vasculitis or iRPGN. Patients were classified
according to a pre-defined diagnostic classification system. Results were
compared with those of 184 disease controls and 740 healthy controls. The
IIF test was performed according to standard methodology; ELISAs had
been standardized among the participants in a previous phase of the study.
The sensitivities of assays in patients were as follows. The sensitivity in
WG was: cANCA 64%, pANCA 21%, anti-PR3 66%, anti-MPO 24%. In
MPA the sensitivity was: cANCA 23%, pANCA 58%, anti-PR3 26%,
anti-MPO 58%. Sensitivity in iRPGN was: cANCA 36%, pANCA 45%,
anti-PR3 50%, anti-MPO 64%. The specificity of assays (related to disease
controls) was: cANCA 95%, pANCA 81%, anti-PR3 87%, anti-MPO
91%. When the results of the IIF test were combined with those of the
ELISAs (cANCA/anti-PR3 positive, pANCA/anti-MPO positive), the
diagnostic specificity increased to 99%. The sensitivity of the combination
of cANCA 1 anti-PR3 or pANCA 1 anti-MPO for WG, MPA or iRPGN
was 73%, 67% and 82%, respectively. From this study we conclude that
the value of the IIF test for ANCA detection can be greatly increased by
the addition of a well standardized antigen-specific ELISA. In a significant
number of patients with idiopathic small vessel vasculitis, however, the
ANCA test results (either in IIF or ELISA) are negative.
Anti-neutrophil cytoplasmic antibodies (ANCA) are now
widely used as diagnostic markers for several forms of idiopathic
systemic vasculitides and idiopathic rapidly progressive glomeru-
lonephritis (iRPGN) [reviewed in 1, 2]. An indirect immunofluo-
rescence test (IIF test) with ethanol-fixed neutrophils can be used
to discriminate a cytoplasmic (cANCA) and a perinuclear
(pANCA) staining pattern. The major target antigens for ANCA
in idiopathic vasculitis have been characterized as enzymes
present in the granules of the neutrophil. The cANCA pattern is
strongly associated with antibodies against proteinase-3 (PR3) [3],
and the pANCA pattern with a number of enzymes, among which
myeloperoxidase (MPO) is the most frequent (others are lacto-
ferrin, elastase, cathepsin-G, and bactericidal/permeability-in-
creasing protein, some of which may cause an atypical staining
pattern of neutrophils as well) [4–8].
A precise definition of the clinical value of ANCA has proven
difficult. First, the unknown etiology of the systemic vasculitides
has given rise to continuous debate about their classification.
Without uniform classification, the diagnostic value of ANCA
cannot be determined, and using ANCA as a disease-specific
diagnostic criterion seems premature. Second, ANCA assays have
not been standardized between laboratories. Standard procedures
for the methodology and nomenclature of the IIF test for ANCA
detection have been defined during ANCA workshops [9, 10]. A
disadvantage of the IIF test for ANCA detection is that the assay
is not antigen-specific. Characterization of the target molecules of
ANCA makes antigen-specific detection in solid phase assays
possible, but such assays have not been standardized until re-
cently, and their clinical value has not been evaluated in a
multi-center setting.
1 Other contributing authors were: I.M. Bajema, J.A. Bruijn, B.E.
Hansen, and M.J.K. Mallat (University Hospital Leiden, Leiden, The
Netherlands); K. de Groot and W.L. Gross (University of Lu¨beck, Bad
Bramstedt, Germany); F. Ferrario (San Carlo Borromeo Hospital, Milan,
Italy); C.D. Pusey (Hammersmith Hospital, London, England, United
Kingdom); Z. Heigl (Karolinska Hospital, Stockholm, Sweden); D. Jayne
and C.M. Lockwood (Addenbrooke’s Hospital, Cambridge, England, United
Kingdom); C.G.M. Kallenberg and J.W. Cohen Tervaert (University Hos-
pital Groningen, Groningen, The Netherlands); F. Mascart-Lemone (Hos-
pital Erasme, Brussels, Belgium); E. Mirapeix (Hospital Clinic I Provincial,
Barcelona, Spain); L.H. Noe¨l (Hoˆpital Necker, Paris, France); B. Ravn Juhl
and C.B. Andersen (Rigshospitalet, Copenhagen, Denmark); A.G. Tzioufas
(National University of Athens, Athens, Greece); J. Wieslander (Wieslab AB,
Lund, Sweden); and R. Waldherr (University of Heidelberg, Heidelberg,
Germany).
2 See Editorial by Jennette, Wilkman, and Falk, p. 796.
Key words: anti-neutrophil cytoplasmic antibodies, systemic vasculitis,
ELISA, immunofluorescence test, proteinase-3, myeloperoxidase, Wege-
ner’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome,
rapidly progressive glomerulonephritis.
Received for publication August 5, 1997
and in revised form October 2, 1997
Accepted for publication October 2, 1997
© 1998 by the International Society of Nephrology
Kidney International, Vol. 53 (1998), pp. 743–753
743
The “European Commission/Measurement and Testing (DG
XII, Science, Research and Development) (EC/BCR) Project for
ANCA Assay Standardisation” is an international multi-center
study that developed and standardized solid phase assays for
ANCA detection. Over the past four years we have established
standardized ELISAs for the detection of anti-PR3 and anti-MPO
antibodies. The results of these development and standardization
studies, which have defined the methodology and validation of
these assays (and not sensitivity and specificity), have been
reported elsewhere [11, 12].
The objective of the present study was to evaluate the diagnos-
tic value of ANCA measurement by IIF tests and by antigen
specific ELISAs in patients with idiopathic systemic vasculitis
[Wegner’s granulomatosis (WG), microscopic polyangiitis
(MPA), classical polyarteritis nodosa (classical PAN) and Churg-
Strauss syndrome (CSS)], classified according to the definitions of
the Chapel Hill consensus conference on the nomenclature of
systemic vasculitides [13]. For this purpose extensive clinical and
histological data were collected from vasculitis patients, from
clinically related disease controls and from healthy controls.
METHODS
Thirteen clinical centers with research laboratory facilities
participated in the collection of patient data, biopsies and sera. Of
the clinical centers, nine were previously involved in ANCA
research. In addition, one commercial laboratory and one state
reference laboratory participated in the serological study.
Patients
Each center was asked to include the last 20 consecutive
patients with idiopathic systemic vasculitis seen in their center
before June 1, 1991. These patients will be referred to as
“historical patients.” In addition, the first 15 consecutive patients
with a similar systemic vasculitis, newly diagnosed or referred for
the first time, after June 1, 1991, were included as “new patients.”
Patients fulfilling one of the following descriptions were included
into the study.
(1.) Patients with clinically suspected WG, no histology re-
quired.
(2.) Patients with iRPGN, renal histology (including immuno-
fluorescence) required. No underlying disease present.
(3.) Patients with histologically proven small vessel vasculitis
and crescentic glomerulonephritis (MPA), histology required
(renal or other site of vasculitis, negative or pauci-immune
fluorescence).
(4.) Patients with classical PAN, CSS, polyangiitis overlap
syndrome or unspecified small/intermediate sized artery vasculitis,
histology required. Underlying diseases such as systemic lupus
erythematosus, rheumatoid arthritis, mixed essential cryoglobu-
linemia, malignancy, serum sickness, drug induced vasculitis,
lymphomatoid granulomatosis, Behc¸et’s disease, Henoch-Scho¨n-
lein purpura, and relapsing polychondritis were excluded.
To avoid a bias towards a positive test result for ANCA,
patients were selected on clinical and histological criteria only, not
on serology. The result of an ANCA test was not taken into
account for entry of patients. To avoid a bias in severity of disease,
all consecutive patients with clinically suspected WG were in-
cluded, even if the classical histological entities (granulomatous
vasculitis and/or glomerulonephritis) were not present in a biopsy.
Because ANCA serology may become negative after the initi-
ation of immunosuppressive therapy, a separate analysis was
performed for patients who had not received any therapy before
the serum was drawn versus patients who did have immunosup-
pressive therapy.
Controls
Two groups of controls were recruited.
Disease controls. A list of possible diagnoses for disease controls
was provided, included secondary vasculitis, various kinds of
glomerulonephritis or granulomatous disease. The patients were
selected on clinical criteria and not on ANCA result. The
diagnoses in these patients was based on solid clinical evidence,
preferably with histology. Fifteen consecutive patients were in-
cluded from each center.
Healthy controls Each center included 50 healthy controls, with
sera derived from the local blood transfusion service. The first 35
healthy controls of each center were age and sex matched with
vasculitis patients entered from that center. The rest were random
donor samples.
Patient data collection
For each subject entered in the study, a patient record book was
completed by the participating center, including age, sex, diagno-
sis and date of diagnosis. For vasculitis patients, data collection at
entry consisted of clinical symptoms and signs of disease activity,
laboratory data including autoimmune and viral serology, radiol-
ogy data, histology data, data on active infections and therapy,
including the time interval between the initiation of immunosup-
pressive drugs and the date the test-serum was drawn. For
historical patients, an accumulation of clinical and histological
data available from the period between the date of diagnosis
(usually after 1989) and the date of entry in the study was scored.
Classification of patients
After entry of patients according to the above entry criteria, all
patients were classified based on data from the record books. For
patient classification a system was designed based on the diagnos-
tic names and definitions adopted by the “Chapel Hill consensus
conference on the nomenclature of systemic vasculitides” [13].
The following diagnostic groups were formed:
Wegener’s granulomatosis. The first group, Wegner’s granulo-
matosis, was divided into the following subgroups: (a) histologi-
cally proven vasculitis with granuloma and/or giant cells in a
biopsy (with or without nephritis); (b) patients with clinical
evidence of at least one airway symptom or sign, compatible with
WG (pulmonary nodules or fixed infiltrates, sinusitis, purulent or
bloody discharge from the nose, saddle nose, otitis media, orbital
pseudotumor, tracheal stenosis). Renal histology in these patients
showed crescentic and/or necrotizing glomerulonephritis with few
or no immune deposits. (c) Patients with clinical evidence of
airway symptoms compatible with WG (see b), but with a histol-
ogy of any organ showing vasculitis with no evidence for glomer-
ulonephritis. (d) Patients had clinical evidence of airway symp-
toms compatible with WG (see b). No histological evidence of the
vasculitis nature of the disease was available.
Microscopic polyangiitis. Patients in this group had histological-
ly-proven crescentic and/or necrotizing glomerulonephritis with
few or no immune deposits, or had histologically proven vasculitis
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of small vessels. Systemic manifestations of disease were compat-
ible with vasculitis. No airway symptoms were compatible with
WG (see above). All patients were hepatitis B antigen negative.
Idiopathic rapidly progressive glomerulonephritis. Patients with
histologically-proven crescentic and/or necrotizing glomerulone-
phritis with few or no immune deposits, without systemic disease
manifestations comprised this group.
Classical polyarteritis nodosa (classical PAN). Patients in this
group had proof of arterial vasculitis (either by angiography or by
biopsy). Criteria of small vessel vasculitis at any biopsy location
(according to Jennette et al [13]) or crescentic glomerulonephritis
at renal biopsy moved the patient into a diagnosis of MPA. All
patients were hepatitis B antigen negative, and none had pulmo-
nary involvement.
Churg-Strauss syndrome. Patients with histologically proven
vasculitis or crescentic glomerulonephritis or giant cells/granu-
loma formation in combination with asthma and eosinophilia
comprised this group.
Pathology review
Renal biopsies. Sections from renal biopsies were reviewed by a
team of four pathologists. Each biopsy was scored independently
by two pathologists according to a standard protocol [14]. The
following items were scored: extra-capillary proliferation, fibrin-
oid necrosis of the glomerular tuft, vasculitis of interstitial vessels,
interstitial granulomas. In case of discrepancies between the data
provided by the reviewing pathologists and those in the patient
record books, the reviewers’ data were used.
Respiratory tract biopsies. All respiratory tract biopsies available
were centrally reviewed by two pathologists. The presence of
vasculitis and of granulomas and/or giant cells was used for
classification of the patients. In case of discrepancies between the
data provided by the reviewing pathologists and those in the
patient record books, the reviewers’ data were used.
Muscle biopsies. Muscle biopsies were reviewed by one pathol-
ogist. The presence of vasculitis and the size of the involved blood
vessels were scored. There were no discrepancies between the
reviewer and the record book data with respect to the presence or
absence of vasculitis, but additional data were added with regard
to vessel size.
Serum collection and storage
For each patient entered in the study, a 4 ml serum sample was
drawn at the time of entry. From historical patients an additional
sample was requested, if available, preferably from the date of the
initial diagnosis. One sample of 2 ml, was sent to the coordinating
center (Leiden) for central storage (220°C) and testing; one
sample was stored locally at 220°C until testing. All samples were
sent in frozen condition.
Indirect immunofluorescence test
Guidelines for the methodology of the IIF test were provided to
all participating centers [15], but were not obligatory. Earlier
investigations in this project indicated that results with the locally
used IIF methodology were comparable between centers with
respect to the ANCA pattern scored [12]. All centers used an
IgG-specific FITC-conjugate. The IIF test was scored as cytoplas-
mic staining (cANCA), perinuclear staining (pANCA), atypical,
or negative staining using the cut-off screening dilution routinely
used in each laboratory. Atypical and negative staining were
combined as negative for specificity calculations. Because titration
results between laboratories showed incomparable results in an
earlier phase of this project [11], titration of sera was not
performed.
ELISAs for anti-PR3 and anti-MPO antibodies
Sera were tested for the presence of anti-PR3 and anti-MPO
antibodies in an ELISA format. For anti-PR3 antibody detection,
three antigens, isolated from human neutrophils by three different
methods, were used (Copenhagen PR3, Raisdorf PR3, and Lei-
den PR3) [11]. For anti-MPO detection one antigen was used
(Copenhagen MPO). ELISAs were performed in a standardized
manner that previously had shown acceptable results and repro-
ducibly low variation between the participating laboratories (for
anti-PR3 assays: intra-assay coefficient of variability (CV) be-
tween 12% and 14%, intra-center CV between 15% and 22%,
between centers CV between 16% and 20%; anti-MPO assay:
intra-assay CV 8%, intra-center CV 21%, between centers CV
34%) [12].
Sera were tested at an initial dilution of 1:50 and the optical
density (OD) value was compared to a 10 point standard curve
included on each ELISA plate. If the optical density was above
90% of the maximal optical density of the standard curve, a serial
dilution was performed. Values were expressed as units/ml de-
rived from the standard curve. All calculations were performed
centrally in the co-ordination center (for further details see [12]).
Cut-off values for assay positivity were derived from receiver
operating characteristic curves, displaying sensitivity versus
1-specificity for various cut-off points. Receiver operating charac-
teristic (ROC) curves were calculated for each ELISA, comparing
results of sera from new patients (WG, MPA, iRPGN, classical
PAN, CSS) with those of the disease controls and the healthy
controls.
Re-testing
Quality control was performed by re-testing 273 sera in three
antigen providing laboratories (Copenhagen, Raisdorf and Lei-
den). The re-tested samples consisted of 108 new patient sera, 97
historical patient sera, 20 healthy control sera and 12 disease
control sera. The sera from each patient category were randomly
selected. The re-test results in the central laboratories were
compared with the results obtained from the local centers.
Double positive sera
Sera that were recorded as positive in at least one of the three
anti-PR3 assay and in the anti-MPO assay (“double positive sera”)
were re-tested centrally in Leiden in the Leiden anti-PR3 assay
and the anti-MPO assay. Fluid phase inhibition experiments were
done on all double positive sera. Sera were pre-incubated with
PR3-Leiden (10 mg/ml) and MPO-Copenhagen (50 mg/ml) for 30
minutes at 37°C. These antigen concentrations were determined
by dose response experiments as being the concentration of
antigen that induced maximal (. 80%) inhibition of the positive
standard serum at a 1:50 dilution. The further ELISA methods
were similar to that described earlier. Inhibition was considered
positive if the difference in units/ml was . 10% between the
inhibited and uninhibited assay. In addition, all these sera were
tested for non-specific binding by testing on plates coated with
human serum albumin instead of antigen.
Double positivity for anti-PR3 and anti-MPO was confirmed by
immunoprecipitation experiments. Immunoprecipitation of 125I-
labeled PR3 (Leiden) and 125I-labeled MPO (Copenhagen) was
EC/BCR Project for ANCA Assay Standardization 745
performed to further establish the reactivity of double positive
sera. To this end replicate tubes containing 200,000 counts per
minute of 125I-labeled PR3 or 125I-labeled MPO in phosphate
buffered saline (PBS) were incubated with 25 ml dilutions of
patient or control sera for two hours at 4°C. This was followed by
addition of 10 ml of a 10% suspension of protein G-sepharose
(Pharmacia). After incubation for one hour at 4°C, the mixtures
were centrifuged and washed extensively with PBS. The final
pellet was re-suspended in 50 ml PBS and 75 ml SDS sample buffer
and boiled for three minutes. One hundred microliters of super-
natant was subsequently subjected to SDS-PAGE analysis. After
drying autoradiograms of the gels were made, and analyzed for
specific immunoprecipitation. As controls, sera known to react
solely with PR3 and MPO were used as well. Anti-PR3 sera
exhibited specific precipitation of 125I-labeled PR3 and no precip-
itation of 125I-labeled MPO while anti-MPO sera only precipi-
tated 125I-labeled MPO.
RESULTS
Patients characteristics
Table 1 shows patient characteristics of the four groups of
patients. A total number of 169 new patients were included in the
study. A total number of 124 patients did not receive immuno-
suppressive drugs prior to entry in the study, 24 received short
duration therapy (,21 days). Sera from all of these patients were
available for evaluation. Of 189 historical patients, 106 sera were
available for testing. Details of diagnoses are shown in Table 1.
A total number of 184 disease controls were included, histolog-
ical confirmation was obtained in 141 (77%). The majority of
these patients had ongoing (active) disease at the time the sample
was drawn. Eighty-three disease controls received some sort of
immunosuppressive therapy at the time the serum was drawn.
Details of diagnoses are given in Table 2. The total number of
healthy controls was 740.
A total of 212 renal biopsies were taken from the included
vasculitis patients, of which 193 biopsies were available for review.
Indirect immunofluorescence test
Table 3 shows data obtained with the IIF test. The sensitivity of
cANCA for WG in new patients was 64%. Perinuclear ANCA
Table 1. Patient characteristics
New
patients
Historical
patients
Disease
controls
Healthy
controls
Number included in
study
169 189 184 740
Serum available 169 106 184 740
Age (years) median
(range)
59 (15–86) 59 (17–90) 46 (7–90) 47 (15–86)
Male: female ratio 1.1:1 1.5:1 1:1.3 1:1.1
Diagnosis
New patients
Historical
patients
No
therapy All
No
therapy All
All diagnoses 126 169 59 106
Wegener’s granulomatosis (all) 73 97 37 75
a WG, granulomas in biopsy 21 31 13 26
b WG, glomerulonephritis in biopsy 37 44 14 28
c WG, vasculitis in biopsy, no GN 7 9 4 8
d WG, no histology support 8 13 6 13
Microscopic polyangiitis 34 44 13 19
Idiopathic RPGN 10 12 3 6
Classical polyarteritis nodosa 5 10 3 3
Churg-Strauss syndrome 4 6 3 3
Abbreviations are: WG, Wegener’s granulomatosus; RPGN, rapidly
progressive glomerlulonephritis.
Table 2. Disease control patients
Diagnosis N
Temporal arteritis 13
Takayasu arteritis 3
Rheumatoid arthritis with vasculitis 7
Systemic lupus erythematosus 45
Mixed essential cryoglobulinemia 9
Henoch-Scho¨nlein purpura 14
Other glomeruloephritis (GN)
Membranous nephropathy 5
IgA nephropathy 13
MPGN 10
Minimal lesions 4
FSGS 2
Crescentic GN (not pauci-immune) 2
Chronic sclerosing GN 6
Immune-complex GN 1
Post-streptococcal GN 2
Anti-GBM disease 6
Tuberculosis 4
Sarcoidosis 14
Ulcerative colitis 7
Crohn’s disease 6
Other vasculitides
Serum sickness 1
Infective endocarditis 3
Visceral sepsis 1
Behc¸et’s disease 3
Scleroderma/MCTD with vasculitis 3
Total 184
Table 3. Sensitivity and specificity of the indirect immunofluorescence
test in patients with systemic vasculitis
Sensitivity %
N cANCA pANCA
cANCA or
pANCA
New patients
Wegener’s granulomatosis 97 62 (64) 20 (21) 82 (85)
Microscopic polyangiitis 44 10 (23) 26 (58) 36 (81)
Idiopathic RPGN 12 4 (36) 5 (45) 9 (81)
Classical polyarteritis nodosa 10 1 (10) 3 (30) 4 (40)
Churg-Strauss syndrome 6 2 (33) 2 (33) 4 (66)
Historical patients
Wegener’s granulomatosis 75 42 (56) 20 (27) 62 (83)
Microscopic polyangiitis 19 2 (13) 11 (69) 13 (82)
Idiopathic RPGN 6 0 (0) 4 (67) 4 (67)
Classical polyarteritis nodosa 3 0 (0) 0 (0) 0 (0)
Churg-Strauss syndrome 3 1 (33) 1 (33) 2 (66)
Specificity %
Control patients
Disease controls 184 9 (95) 35 (81) 44 (76)
Healthy controls 740 15 (98) 30 (96) 45 (94)
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(pANCA) were present in 21% of WG patients. The combination
of either a cANCA or a pANCA therefore reached a sensitivity of
85%. The sensitivity for cANCA in WG patients with renal
disease was similar to the WG patients without renal disease (both
64%). The pANCA was more prevalent in patients with histolog-
ically proven glomerulonephritis (30%) than in patients without
renal disease (10%).
The pANCA were more prevalent than cANCA in MPA (58%
vs. 23%) and iRPGN patients (45% vs. 36%). The sensitivity of
cANCA 1 pANCA was 81% in MPA and 82% in iRPGN. Ten
new patients with classical PAN were included, four were ANCA
positive. Six CSS patients were included, four were ANCA
positive.
The results obtained with sera from historical patients showed
results comparable to those of new patients (Table 3). There was
no significant difference in sensitivity between treated or un-
treated patients.
Of the disease controls 35 (19%) patients were positive for the
pANCA pattern [15 SLE, 5 ulcerative colitis, 4 Crohn’s disease, 3
temporal arteritis, 2 mixed cryoglobulinemia, 2 Goodpasture
syndrome, 1 rheumatoid vasculitis, 1 Henoch-Scho¨nlein purpura
(HSP), 1 sarcoid and 1 IgA nephropathy patient]. Eight patients
had a cANCA pattern (2 SLE, 2 sarcoid, 1 temporal arteritis, 1
HSP, 1 membraneous nephropathy, 1 IgA nephropathy). Of the
healthy control sera 2% were recorded as cANCA positive, 4% as
pANCA positive, resulting in a specificity of the IIF test (cANCA
and pANCA together) of 76% towards disease controls and 94%
towards healthy controls.
Fig. 1. ELISA results from all new patients
obtained with the Copenhagen anti-PR3 ELISA
(A) and anti-MPO ELISA (B). Results with
anti-PR3 ELISAs from Leiden and Raisdorf
were comparable to that obtained with the
Copenhagen ELISA. Abbreviations are: WG,
Wegener’s granulomatosis; MPA, microscopic
polyarteritis; iRPGN, idiopathic rapidly
progressive glomerulonephritis; cPAN, classical
polyarteritis nodosa; CSS, Churg-Strauss
syndrome; DC, disease controls; HC, healthy
controls.
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Atypical fluorescence, defined as fluorescence of neutrophils
that does not resemble the typical cytoplasmic or (peri)nuclear
pattern, was considered negative for analysis.
ELISA results
Figure 1 shows the results of all evaluable sera from new
patients in the anti-PR3 ELISA (Copenhagen) and in the anti-
MPO ELISA. There were large differences in the concentration
of antibodies against PR3 and MPO in the patients as measured
by ELISA. Disease controls were never more than tenfold higher
than the normal limit in anti-PR3 assays, and (with one exception)
in the anti-MPO assay.
To ensure optimal sensitivity and specificity, receiver operating
characteristic (ROC) curves were calculated for each ELISA (Fig.
2). A specificity approximating 90% towards disease control
patients was considered the minimum required. This corre-
sponded to a cut-off point between “normal” and “abnormal”
values of 500 U/ml for the anti-PR3 assays, and 1500 U/ml for the
Fig. 2. Receiver operating characteristic (ROC) curves of Raisdorf ELISA for the detection of anti-PR3 antibodies and the anti-MPO ELISA. Symbols
are: (M) values for healthy controls; (f) disease controls. (A) Anti-PR3 ELISA. (B) Anti-MPO ELISA. Each point represents the relation between
sensitivity and 1-specificity for one cut-off value. The results obtained with the Copenhagen and Leiden anti-PR3 assays were comparable with the
Raisdorf anti-PR3 assay. Abbreviations are: DC, disease control, HC, healthy control.
Table 4. Sensitivity and specificity of anti-PR3 and anti-MPO ELISAs in patients with systemic vasculitis, disease controls and healthy controls
N
Sensitivity %
Anti-proteinase 3
Anti-myeloperoxidaseCopenhagen Raisdorf Leiden
New Patients
Wegener’s granulomatosis 97 63 (65) 64 (66) 65 (67) 23 (24)
Microscopic polyangiitis 44 11 (25) 12 (27) 12 (27) 26 (58)
Idiopathic RPGN 12 6 (50) 7 (55) 7 (58) 8 (64)
Classical polyarteritis nodosa 10 1 (10) 12 (13) 2 (20) 4 (38)
Churg-Strauss syndrome 6 2 (33) 2 (33) 1 (17) 3 (50)
Historical patients
Wegener’s granulomatosis 75 41 (55) 43 (58) 47 (63) 22 (29)
Microscopic polyangiitis 19 5 (26) 9 (46) 5 (26) 10 (54)
Idiopathic RPGN 6 2 (33) 1 (20) 1 (17) 5 (80)
Classical polyarteritis nodosa 3 1 (33) 0 (0) 0 (0) 0 (0)
Churg-Strauss syndrome 3 1 (33) 3 (100) 2 (67) 0 (0)
Specificity %
Control patients
Disease controls 184 26 (86) 20 (89) 24 (87) 17 (91)
Healthy controls 740 15 (98) 7 (99) 15 (98) 30 (96)
Cut-off values were 500 U/ml for anti-PR3 assays and 1500 U/ml for anti-MPO assay. RPGN is rapidly progressive glomerulonephritis. New patients
were newly diagnosed after the start of the study, historical patients were analyzed retrospectively.
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anti-MPO assay, as compared with the anti-PR3 and anti-MPO
standard sera used (these were both set at an arbitrary level of
10,000 U/ml).
Wegener’s granulomatosis. The sensitivity of anti-PR3 antibodies
using the above mentioned normal limits for new patients with
WG was 65 to 67% (Table 4). The sensitivity in patients with
classical histology (granulomas) as compared to those with the
clinical picture of WG, but with histological evidence only of
vasculitis or crescentic nephritis, was similar (data not shown).
Anti-MPO antibodies were present in 24% of all WG patients.
Patients with biopsy-proven crescentic glomerulonephritis had
anti-MPO more frequently than patients without renal disease
(32% vs. 18%). Therapy with immunosuppression did not change
the sensitivity of the anti-PR3 or anti-MPO assay. There was no
difference between historical and new patients (Table 4).
Microscopic polyangiitis. A total of 58% of new patients with
MPA had anti-MPO antibodies, and 25 to 27% had anti-PR3
antibodies. The percentages in historical patients were similar, but
immunosuppressive therapy did not change the sensitivity (Table
4).
Idiopathic pauci-immune crescentic glomerulonephritis. Anti-
PR3 antibodies were present in 45% to 55% of patients, anti-
MPO antibodies were present in 64% (Table 4).
Classical PAN and Churg-Strauss syndrome. The number of
patients with these diseases was low. Anti-PR3 antibodies were
present in 1 of 10 new patients with classical PAN, and in 2 of 6
new patients with CSS. Anti-MPO were present in 4 of 10 new
patients with classical PAN, 3 of 6 CSS patients were anti-MPO
positive (Table 4).
Control subjects. The definition of the normal cut-off of the
ELISAs was based on a specificity approximating 90% towards
disease controls. This resulted in a specificity for the anti-PR3
assays of 86%, 87% and 89%, respectively, and for the anti-MPO
assay of 91%. Towards healthy controls, the specificity was 98% to
99% for the anti-PR3 assays and 96% for the anti-MPO assay.
There was an equal distribution among diagnoses of disease
controls who were positive for anti-PR3 and anti-MPO ANCA.
Six of 45 (13%) of sera from patients with SLE nephritis were
positive for anti-PR3 antibodies and 7 of 45 for anti-MPO
antibodies (Fig. 3).
Combination of IIF and ELISA
The results from the IIF test were combined with the ELISA
results (Table 5). For the combination of cANCA with anti-PR3
antibodies, the sensitivity for new WG patients was 56 to 58%, and
for pANCA with anti-MPO it was 16%. For MPA, the sensitivity
of the combined assays was 12 to 16% for cANCA/anti-PR3 and
49% for pANCA/anti-MPO. For iRPGN the sensitivity was 36%
and 46%, respectively. The specificity towards disease control
patients increased to 99%, towards healthy controls to 100% after
combining the IIF test with ELISA. (Table 5).
Re-testing of sera
A total of 237 sera were re-tested in the central laboratories.
The correlation coefficient for the results obtained in the center of
origin and the central laboratory for the assays was 0.94 (Copen-
hagen PR-3), 0.83 (Raisdorf PR3), 0.84 (Leiden PR3) and 0.84
(MPO) (P , 0.0001 for all assays). There was no significant
difference between the test and re-test results (paired t-test, P 5
0.48 for Copenhagen anti-PR3 ELISA, P 5 0.66 for Raisdorf
anti-PR3 ELISA, P 5 0.37 for Leiden anti-PR3 ELISA, P 5 0.48
for the anti-MPO ELISA).
Double positive sera
Of 275 historical and new patient sera, 184 disease control sera
and 740 healthy control sera tested (total 1204 sera), 32 were
positive in both the anti-PR3 Copenhagen ELISA and the anti-
MPO ELISA, 35 in the Raisdorf anti-PR3 and anti-MPO ELISA,
and 33 in the Leiden anti-PR3 and anti-MPO ELISA. This means
that about 15% of all anti-PR3 positive sera were double positive
(20% of all anti-MPO positive sera). All these 100 sera were
re-tested in the co-ordinating laboratory (Leiden), after which
only ten showed persistent double reactivity. Seven of these 10
sera showed predominant positivity against MPO with low-posi-
tive anti-PR3 values. Two had high anti-PR3 titers with low-
positive anti-MPO. One was strongly positive in both assays. Fluid
phase inhibition ELISA showed inhibition of anti-PR3 and anti-
MPO reactivity in eight out of these ten. Only one of these ten
showed nonspecific binding to the ELISA plate. Results obtained
with the double positive sera are listed in Table 6.
Of the ten double positive sera nine came from patients with
idiopathic systemic vasculitis, and one from a patient with sys-
temic lupus erythematosus (SLE). Two sera could not be inhibited
by fluid phase antigen, one from an SLE patient, the other from
a patient with classical PAN. All other patients had histological
evidence of glomerulonephritis, two patients were classified as
WG, five as MPA and one as idiopathic RPGN (Table 6). The
SLE serum also showed reactivity with plates coated with human
albumin instead of antigen (non-specific binding).
DISCUSSION
This study investigated the diagnostic value of the IIF test and
newly developed and standardized ELISAs for the detection of
ANCA in patients with idiopathic systemic vasculitis in an inter-
national multi-center setting. The results indicate that, in com-
parison with the sole usage of the IIF test for ANCA detection,
the combination of the IIF test with antigen specific ELISAs for
anti-PR3 and anti-MPO antibodies results in an approximately
10% lower sensitivity. However, with this combination the speci-
ficity increased to 98% towards disease control patients. Control
patients were selected on the basis of diagnosis with clinical signs
and symptoms reminiscent of the proband primary vasculitis
patients, and thus sometimes posed differential diagnostic prob-
lems.
Early reports on the IIF test for ANCA detection showed a high
sensitivity and specificity for active WG and MPA [16–19]. These
conclusions were drawn on the basis of results obtained with the
standard IIF test, often in combination with solid phase assays for
ANCA detection using purified antigens or partially purified
neutrophil extracts. Others have questioned the diagnostic value
of ANCA. Davenport et al reported a low specificity (77%) of
ANCA in patients with respiratory tract symptoms [20, 21].
Results from a prospective cohort study among rheumatology
patients suggested that the sensitivity of cANCA for WG was even
lower (28% in patients with ACR-criteria defined WG) [22].
However, the performance of the diagnostic criteria used in this
study (ACR criteria [23]) must be questioned since 19 of 25 (76%)
of diagnoses assigned were proven to be wrong during later
follow-up. A recent meta-analysis of all published literature on the
diagnostic value of cANCA for WG revealed an overall sensitivity
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of 66%, with values of up to 91% in patients with active disease
[24]. The specificity of cANCA varied between 98% and 99%;
however, the authors noted that large groups of individuals with a
low pre-test probability for WG were used as controls [24].
We have tried to avoid several types of biases that could
influence the results of the evaluation of ANCA assays. Selection
of patients for severity of disease was avoided by including all
consecutive patients. Referral bias of patients could not be
prevented completely, because mainly specialized centers partic-
ipated in this study, involving several subspecialties: internal
medicine, nephrology, rheumatology and otolaryngology. Patients
with WG often lack histological confirmation of the disease, and
such patients were only included if the clinical picture was
convincing. Patients were included on clinical grounds, not on the
basis of ANCA results. All patients were subsequently classified
using the names and definitions adopted from the “Chapel Hill
consensus conference on vasculitis nomenclature.” This classifi-
cation was undertaken centrally, formally based upon objectively
scored signs and symptoms, and upon centrally reviewed histol-
ogy, in order to avoid differences in nomenclature between
centers. All sera were tested in a blinded manner. In this way we
tried to avoid some problems that have caused debate concerning
the clinical value of ANCA in the past.
The identification of the target antigens most frequently recog-
nized by ANCA in primary vasculitides has facilitated the devel-
opment of solid phase assays [3, 19, 25–28]. A comparison of such
assays at the start of this project showed comparable results
among anti-MPO positive sera between centers, but large vari-
ability in results obtained with assays for the measurement of
antibodies to cANCA-related antigen [11]. The main reason for
this variability appeared to be differences in antigen purity and
coating conditions. Therefore, a major point of this project was
Fig. 3. Results of anti-PR3 and anti-MPO
ELISA of disease control patients in (A) PR3,
Leiden, and (B) MPO, Copenhagen.
Abbreviations are: TEMP ART, temporal
arteritit; RV, rheumatoid arthritis with
vasculitis; TAKAY, Takayasu’s disease; SLE,
systemic lupus erythematosus; CRYO, essential
mixed cryoglobulinemia; HSP, Henoch-
Scho¨nlein purpura; TBC/SARC, tuberculosis or
sarcoid; GLOM, glomerulonephritis; other
VASC, other kinds of vasculitis; IBD,
inflammatory bowel disease. For patient
numbers and further subclassifications, see
Table 2.
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the isolation of purified PR3 for use in standardized assays. The
results of the methods and standardization study have been
reported elsewhere [12].
We confirm that ANCA detected by the IIF test (cANCA or
pANCA) are a sensitive marker for WG, MPA and “pauci-
immune” iRPGN, sometimes referred to as renal limited vascu-
litis with sensitivity scores ranging from 81% to 85%. The low
specificity, however, (76%), which is mainly caused by positive
pANCA in disease controls, is a strong disadvantage. pANCA in
disease controls can be caused by the presence of anti-nuclear
antibodies, especially in SLE patients. The use of ELISA using
purified antigens as an alternative method could not improve the
specificity without a significant loss in sensitivity. However, if the
IIF test was combined with ELISA using PR3 and MPO, the
specificity was improved to 98%, with a sensitivity loss of only
10%. Data from the retrospective part of this study showed
comparable results to those of the prospective part of the study. In
patients who had been on immunosuppressive therapy for more
than three weeks, the sensitivity of the assays was only slightly
lower than in patients with no or short duration therapy. The
numbers of patients with classical PAN and CSS were too low to
allow conclusions on the prevalence of ANCA in these types of
vasculitis.
A significant number of sera were positive in both the anti-PR3
and the anti-MPO antibody assay. Most of these results were
lower than twice the cut-off value. Re-testing of these sera in the
co-ordinating laboratory indicated that only some double positive
results could be confirmed. Antigen specific inhibition of most of
these sera could be achieved by adding fluid phase antigen to the
serum prior to incubation. It was less easy to demonstrate double
positivity by immune precipitation analysis, presumably because
the interaction in the fluid phase between PR3 and MPO with
their respective antibodies may be different from the interaction
with solid phase antigen. From this we can conclude that true
double positivity is a rare event. However, in routine practice
double positivity in ELISA is quite frequent, due to low positive
results.
The use of disease controls with conditions that may show
similarities to WG, MPA or iRPGN causes a drop in specificity
compared to that observed with healthy controls for comparison
Table 5. Sensitivity and specificity of the combination of IIF-test and ELISA results in patients with systemic vasculitis
N
Sensitivity %
cANCA 1 anti-PR3 pANCA 1
anti-MPO
cANCA/PR3a or
pANCA/MPOCopenhagen Raisdorf Leiden
New patients
Wegener’s granulomatosis 97 55 (57) 56 (58) 54 (56) 16 (16) 71 (73)
Microscopic polyangiitis 44 7 (16) 5 (12) 7 (16) 22 (49) 30 (67)
Idiopathic RPGN 12 4 (36) 4 (36) 4 (36) 6 (46) 10 (82)
Classical polyarteritis nodosa 10 1 (10) 1 (10) 1 (10) 1 (10) 2 (20)
Churg-Strauss syndrome 6 2 (33) 2 (33) 0 (0) 2 (33) 3 (56)
Historical patients
Wegener’s granulomatosis 75 32 (43) 31 (41) 36 (48) 15 (19) 46 (62)
Microscopic polyangiitis 19 1 (5) 1 (6) 1 (6) 7 (36) 8 (42)
Idiopathic RPGN 6 0 (0) 0 (0) 0 (0) 4 (60) 4 (60)
Classical polyarteritis nodosa 3 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Churg-Strauss syndrome 3 1 (33) 0 (0) 1 (33) 0 (0) 1 (33)
Specificity %
Control patients
Disease controls 184 1 (99) 1 (99) 1 (99) 2 (99) 3 (98)
Healthy controls 740 1 (100) 1 (100) 1 (100) 0 (100) 1 (100)
RPGN is rapidly progressive glomerulonephritis. New patients were newly diagnosed after the start of the study, old patients were analyzed
retrospectively.
a Anti-PR3 result is average of the sensitivity of the 3 anti-PR3 ELISAs
Table 6. Results of consistently double positive sera
Diagnosis PR3-COa PR3-RSa PR3-LEa MPOa IIF
Inhibition
Immuno-
precipitation
PR3 MPO PR3 MPO
1 WG 552 658 404 6956 pANCA 1 1 1 1
2 MPA 114 295 545 12729 atyp ANCA 1 1 6 2
3 MPA 519 597 378 5908 pANCA 1 1 2 1
4 MPA 332 533 495 15939 pANCA 1 1 2 1
5 MPA 1246 1566 599 263743 pANCA 1 1 2 1
6 MPA 349 563 545 25944 negative 1 1 nd nd
7 WG 3804 3370 1971 2432 cANCA 1 1 2 2
8 iRPGN 4452 2532 1908 48621 pANCA 1 1 nd nd
9 SLEb 556 893 313 17709 negative 2 2 nd nd
10 classical PAN 6831 4963 2184 3178 cANCA 1 2 nd nd
Sera were tested in ELISA and in the IIF-test. Inhibition was performed by fluid phase antigen (see text). All figures are in units/ml.
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with the proband population. Since the only relevant control
population is the former, cut-off values of the assays should not be
defined on the basis of healthy donor values, but rather on values
seen in the proper disease controls using ROC curve analysis,
which allows selection of high diagnostic specificity over sensitiv-
ity.
From this study we conclude that direct ELISAs using purified
PR3 are not in themselves more sensitive than the cANCA test. If
a high specificity is selected for, cANCA is more specific at a
comparable sensitivity level. However, by combining the IIF test
with antigen specific ELISAs for PR3, ANCA serology remains a
very specific tool for the diagnosis WG especially in newly
diagnosed patients. The rather frequent occurrence of pANCA in
Wegener’s patients is somewhat unexpected, but may relate to the
classification system used in this study. Patients with airway
symptoms other than pulmonary hemorrhage were classified as
WG, while in earlier studies some would have been diagnosed as
MPA. The low specificity of pANCA alone was expected due to
the known occurrence of pANCA in some of the disease control
groups (rheumatoid arthritis, ulcerative colitis and infective en-
docarditis) as well as the presence of anti-nuclear antibodies in
patients with systemic lupus erythematosus, which makes the IIF
interpretation difficult. When positive pANCA was combined
with presence of MPO-ANCA at a cut-off level of 1500 U/ml, a
very high specificity for proband diagnoses was seen, both towards
healthy controls and disease controls.
In conclusion, the value of ANCA tests for differential diagno-
sis of idiopathic necrotizing small vessel vasculitis can be opti-
mized by combining two assay methods (the IIF test together with
standardized antigen specific ELISAs choosing cut-off levels
allowing a specificity of 90% towards disease controls). These
measures are absolutely necessary to improve the diagnostic
significance of ANCA, to heighten the quality of scientific com-
munication regarding vasculitides and to avoid false interpreta-
tion of positive results and, hence, unnecessary therapeutic mea-
sures.
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